F S&P 500
4,994.50 -54.50 (-1.08%) F Dow Jones
37,647.00 -360.00 (-0.95%) F Nasdaq
17,317.25 -230.00 (-1.31%) E-mini Russell 2000 Index Futur
1,933.30 -24.80 (-1.27%) Petróleo
85.17 +2.44 (+2.95%) Oro
2,406.00 +8.00 (+0.33%)
Protagonist Therapeutics, Inc. (PTGX)
Fuera de horario:
Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark, CA 94560-1160
United States
510 474 0170
https://www.protagonist-inc.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 112
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Dinesh V. Patel Ph.D. | CEO, President, Secretary & Director | 883.46k | N/D | 1957 |
| Dr. Suneel K. Gupta Ph.D. | Chief Development Officer | 640.89k | N/D | 1959 |
| Dr. Mark Smythe Ph.D. | Founder & VP Technology | N/D | N/D | 1965 |
| Mr. Asif Ali | Executive VP & Chief Financial Officer | N/D | N/D | 1974 |
| Mr. Mohammad Masjedizadeh Ph.D. | Executive VP & Chief Technical Officer | N/D | N/D | N/D |
| Mr. Matthew M. Gosling | Executive VP & General Counsel | N/D | N/D | 1971 |
| Ms. Carena Spivey | Head of HR & Senior VP of Human Resources | N/D | N/D | N/D |
| Dr. Ashok Bhandari Ph.D. | Executive VP & Chief Drug Discovery and Preclinical Development Officer | N/D | N/D | 1964 |
| Mr. Carter J. King | Executive Vice President of Business Development | N/D | N/D | 1971 |
| Ms. Abha Bommireddi | Executive Vice President of Portfolio & Program Management | N/D | N/D | N/D |
Descripción
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Protagonist Therapeutics, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 7; Derechos del accionista: 7; Compensación: 8.
